These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25678187)

  • 21. [Expression of basic fibroblast growth factor and its receptor in renal cell carcinoma].
    Zhong H; Deng F; Kong X
    Zhonghua Wai Ke Za Zhi; 1996 Nov; 34(11):651-4. PubMed ID: 9590749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
    Tomita Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma.
    Procopio G; Verzoni E; de Braud F
    Oncology; 2013; 84(1):39-42. PubMed ID: 23076302
    [No Abstract]   [Full Text] [Related]  

  • 28. Non-clear cell renal cell carcinoma, part 2: therapy.
    Valenca LB; Hirsch MS; Choueiri TK; Harshman LC
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):383-91. PubMed ID: 26352894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biomarker for molecular targeting therapy against renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cell cancer.
    Hutson TE; Figlin RA
    Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGFR1 is associated with c-MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti-angiogenic therapy.
    Park JY; Kim PJ; Shin SJ; Lee JL; Cho YM; Go H
    Histopathology; 2020 May; 76(6):838-851. PubMed ID: 31990416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
    Brooks AN; Kilgour E; Smith PD
    Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the management of renal cell cancer.
    Pécuchet N; Fournier LS; Oudard S
    Oncology; 2013; 84(1):22-31. PubMed ID: 23076127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting fibroblast growth factor receptor pathway in breast cancer.
    Criscitiello C; Esposito A; De Placido S; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model.
    Tsimafeyeu I; Zaveleva E; Stepanova E; Low W
    Invest New Drugs; 2013 Dec; 31(6):1436-43. PubMed ID: 24026432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.
    Wada Y; Takahashi W; Kawano Y; Eto M
    Int J Urol; 2012 Apr; 19(4):284-95. PubMed ID: 22452375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.